Commercial What do physicians think about biosimilars?

What do physicians think about biosimilars?

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Commercial Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Features Why are We Still Shortchanging Women in the Workplace?

Why are We Still Shortchanging Women in the Workplace?

Why would any CEO tolerate a corporate culture that holds people back?

Commercial 4 trends with the potential to change behavior in the patient journey

4 trends with the potential to change behavior in the patient journey

It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.

Therapeutic Focus Top 25 infectious disease products in 2015

Top 25 infectious disease products in 2015

To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.

Therapeutic Focus Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Therapeutic Focus Competition may threaten Gilead as market leader

Competition may threaten Gilead as market leader

Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.

Therapeutic Focus Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

Therapeutic Focus With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

The bar for market success has been set high for baricitinib.

Therapeutic Focus Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.

Agency 2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Features

2016 Pharma Report: Index of top 20 drugmakers

The index of the top 20 drugmakers from the 2016 pharma report.

Corporate

20. Bristol-Myers Squibb

Immuno-oncology was the story at Bristol-Myers Squibb in 2015.

Corporate

19. Valeant

So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.

Corporate

18. Biogen

Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.

Corporate

17. Mylan

After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

Corporate

16. Boehringer Ingelheim

In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.

Corporate

15. GlaxoSmithKline

The year 2015 was one of restructuring for GlaxoSmithKline.

Corporate

14. Novo Nordisk

Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.

Corporate

13. Eli Lilly

Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.

Corporate

12. AbbVie

Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.

Corporate

11. Allergan

Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.

Agency

10. Sanofi

The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.

Corporate

9. Roche

On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.

Corporate

8. Amgen

As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.

Corporate

7. Teva

Analysts agree that Teva is casting a healthy financial shadow.

Corporate Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

Agency Post Pfizer, Allergan faces the future

Post Pfizer, Allergan faces the future

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

Corporate

6. AstraZeneca

AstraZeneca has embarked on what's likely to be a long, rough ride.

Corporate

5. Pfizer

Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

Corporate

4. Novartis

There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

Corporate

3. Merck

Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.

Features

2. Johnson & Johnson

J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.

Corporate

1. Gilead Sciences

Gilead's current and future success lies in the hands of its antiviral franchise.

MMM Hall of Femme MM&M's Hall of Femme: 20 women to watch

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

MMM Hall of Femme MM&M's Hall of Femme: 16 women leaders who changed the industry

MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

Pipeline Infographic: the growing biosimilar market in the U.S.

Infographic: the growing biosimilar market in the U.S.

The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.

Corporate Be a better mentor, says Baxalta's Leonardi

Be a better mentor, says Baxalta's Leonardi

Too often left undiscussed is that a powerful business case can be made for more frequent and focused mentorship.

Agency Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Campaigns Using humor: Why pharma doesn't need to fear social media

Using humor: Why pharma doesn't need to fear social media

Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.

Features Guidemark Health's Fascetti on Ads that Change Behavior

Guidemark Health's Fascetti on Ads that Change Behavior

Curious what a 2016 Lions Health judge thinks about creativity? Here's what defines behavior-changing creativity for Guidemark Health's Tina Fascetti.

Agency At Work With: Cello Health's Jon Bircher

At Work With: Cello Health's Jon Bircher

"I continue to look for ways to stretch myself or ways I can get involved or influence the business," said the new CCO of Cello Health.

Features Which brands spent the most on professional ads in 2015?

Which brands spent the most on professional ads in 2015?

Here are the brands and companies that advertised the most on professional ads in 2015.

Features When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

Sponsored Game Changers 2016: MicroMass

Game Changers 2016: MicroMass

Sponsored Game Changers 2016: 4INFO

Game Changers 2016: 4INFO

Sponsored Game Changers 2016: Skipta

Game Changers 2016: Skipta

Sponsored Game Changers 2016: PDR

Game Changers 2016: PDR

Sponsored Game Changers 2016: XL Alliance

Game Changers 2016: XL Alliance

Sponsored

2016 Game-Changing Companies

Commercial What 10 innovation teams look like

What 10 innovation teams look like

Learn about Merck's new innovation team as well as read profiles of 9 other teams at companies such as Google and Johnson & Johnson.

Commercial From the Editor

From the Editor

Healthcare innovation teams are at a unique point. They've moved from ideating to innovating and have structured themselves accordingly.

Agency Infographic: Better promotion of clinical trials

Infographic: Better promotion of clinical trials

Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.

Careers Retaining talent: How pharma can compete with Google

Retaining talent: How pharma can compete with Google

As tech behemoths like Google are attempting to poach the best and brightest, executives from pharma companies and agencies share new retention tactics.

Campaigns 2015 DTC spending: All the data in one place

2015 DTC spending: All the data in one place

Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.

Campaigns A ranking of 2015's DTC Ads

A ranking of 2015's DTC Ads

Great DTC pharma advertising during the last year or so has been "sparse," says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.

Campaigns DTC Report 2016: Gut Check

DTC Report 2016: Gut Check

DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.

MM&M Awards How to win an MM&M award: the do's and the don'ts

How to win an MM&M award: the do's and the don'ts

Tip: Don't charge your intern with assembling your entry. Read more from our checklists of do's and don'ts, and don't forget that entries are due April 11.

Data/Analytics Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Commercial Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Pipeline Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Commercial Top 25 respiratory products, 2014-2015

Top 25 respiratory products, 2014-2015

GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).

Commercial How My GI Health changed the conversation for patients

How My GI Health changed the conversation for patients

The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.

Commercial Ironwood's McCourt bets big on data and the patient-physician dialogue

Ironwood's McCourt bets big on data and the patient-physician dialogue

Tom McCourt says he's "a marketing guy who hopefully understands a little about drug development" even as he guided drugs like Prilosec to market.

Agency Giant's McCasland on chasing novelty

Giant's McCasland on chasing novelty

McCasland has witnessed the agency's evolution from a small startup to a 150-strong team with offices in San Francisco and Philadelphia.

Features Omnichannel Marketing 2016: From the Editor

Omnichannel Marketing 2016: From the Editor

We present this supplement, a road map of tips, trends, and data to help healthcare brands reach multichannel engagement.

Features How to seize your omnichannel moment

How to seize your omnichannel moment

Patients and doctors are looking for orchestrated customer engagement and expect omnichannel excellence. Are healthcare marketers ready?

Features Lehman Millet's Lotterman Breaks Down Ads That Inspires Us

Lehman Millet's Lotterman Breaks Down Ads That Inspires Us

When a brand takes the time to fill in the backstory, that's when the real connections begin.

Agency At Work With: McCann Health North America's Tammy Fischer

At Work With: McCann Health North America's Tammy Fischer

"Nothing is as powerful as when you see the courage on a patient's face, completely unknown to you, with the will and determination to fight a disease," said the chief growth officer of McCann Health North America.

Agency Omnichannel Marketing 2016: AbelsonTaylor

Omnichannel Marketing 2016: AbelsonTaylor

In 1981 we started an agency because we wanted to chart our own course. Thirty-five years later we have become the largest independent healthcare agency of record in the world.

Agency Omnichannel Marketing 2016: Rx Edge

Omnichannel Marketing 2016: Rx Edge

Since our inception, in 2000, pharmaceutical marketers have counted on Rx EDGE to help them acquire and educate new patients while increasing brand awareness.

Agency Omnichannel Marketing 2016: Clinical Mind

Omnichannel Marketing 2016: Clinical Mind

ClinicalMind is a full-service medical communications company with extensive experience in specialty therapeutic areas.

Agency Omnichannel Marketing 2016: Skipta

Omnichannel Marketing 2016: Skipta

Skipta is the leading social network of specialized online medical communities for verified healthcare professionals.

Agency Omnichannel Marketing 2016: HealthLink Dimensions

Omnichannel Marketing 2016: HealthLink Dimensions

HealthLink Dimensions provides healthcare data solutions to healthcare and life-science organizations to improve master data management, compliance, and marketing initiatives.

Agency Omnichannel Marketing 2016: 4INFO

Omnichannel Marketing 2016: 4INFO

4INFO offers a mobile-first ad tech platform that enables national pharma brand advertisers to target audiences across mobile devices and desktops precisely and then measure the success of those campaigns.

Features 5 industry execs discuss how to harmonize healthcare campaigns

5 industry execs discuss how to harmonize healthcare campaigns

Here are points of view from five sector pros on harmonizing healthcare campaigns in today's complex marketing world.

Features Omnichannel marketing tech opens new doors for engagement

Omnichannel marketing tech opens new doors for engagement

Omnichannel as company commitment is nothing new to technical marketing in pharma. Marketers now need a broader omnichannel funnel continuously open to deeper customer engagement.

Features

Omnichannel Marketing 2016: Healthcare and marketing partners

A showcase of this supplement's healthcare and marketing partners

Technology Pharma turns to mobile, population data to market to docs

Pharma turns to mobile, population data to market to docs

Discover why even digitally native physicians can no longer abide the flood of information e-sent their way.

Pipeline Sensors, technology open the door to new era for clinical trials

Sensors, technology open the door to new era for clinical trials

Welcome to the mobile era for clinical trials, in which phone and tablet technology promise to upend a costly and unwieldy process.

Pipeline Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Campaigns 2016 Healthcare Marketers Trend Report: Guidemark Health's Matt Brown on the numbers

2016 Healthcare Marketers Trend Report: Guidemark Health's Matt Brown on the numbers

"Globally, you're seeing a lot more unbrand­ed campaigns," he explains.

Campaigns How is pharma shifting its marketing budgets?

How is pharma shifting its marketing budgets?

Although the healthcare industry is undergoing rapid change, marketing approaches are evolving in fits and starts. Learn more in the 2016 Healthcare Marketers Trend Report.

Commercial TMC's McGuire preps CRE antibiotic for market

TMC's McGuire preps CRE antibiotic for market

The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.

Data/Analytics 6 insights into today's healthcare consumer

6 insights into today's healthcare consumer

Finn Partners surveyed 1,000 adults to understand how often young Americans change doctors and how they talk to pharmacists.

Therapeutic Focus Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.

Therapeutic Focus Top 25 orphan drugs, by 2015 global sales

Top 25 orphan drugs, by 2015 global sales

Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.

Therapeutic Focus Rare disease drugs facing questions over prices, incentives

Rare disease drugs facing questions over prices, incentives

With drugs treating rare diseases priced at sky-high levels, can the healthcare system shoulder the financial burden they impose?

Agency InVentiv Health's O'Kane on using humor to combat change

InVentiv Health's O'Kane on using humor to combat change

"Under no circumstances should you lose your sense of humor," says the PR group's new US managing director.

Features Sound Healthcare's Hack Delves Into Ads With Great Strategy

Sound Healthcare's Hack Delves Into Ads With Great Strategy

A great strategy humanizes a customer insight by tapping into a universal human truth.

At Work With At Work With: FreshBlood's Robert Finkel

At Work With: FreshBlood's Robert Finkel

Greatest professional challenge? "Leaving the security of a big, well-established ad agency and deciding to open my own independent ad agency."

Features At Work With: Digitas Health LifeBrands' Jennifer Durante

At Work With: Digitas Health LifeBrands' Jennifer Durante

"The view reminds me to always try to see the big picture, to not get too caught up in the trees."

OPINION

Email Newsletters